{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:55:53Z","timestamp":1786992953481,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jneuroim.2013.08.011","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T04:32:38Z","timestamp":1377923558000},"page":"123-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype"],"prefix":"10.1016","volume":"264","author":[{"given":"Catherine","family":"Milch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wyant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asit","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2013.08.011_bb0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2014unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0030","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the alpha4beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0035","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","article-title":"Antagonizing the alpha4beta1 integrin but not alpha4beta7 inhibits leukocytic infiltration of the CNS in rhesus EAE","volume":"190","author":"Haanstra","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/smim.1999.0168","article-title":"Leukocyte traffic in the central nervous system: the participants and their roles","volume":"11","author":"Hickey","year":"1999","journal-title":"Semin. Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.jneuroim.2013.08.011_bb0045","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3949\/ccjm.78.s2.02","article-title":"History and current concepts in the pathogenesis of PML","volume":"78","author":"Major","year":"2011","journal-title":"Cleve. Clin. J. Med."},{"issue":"5 Suppl. 1","key":"10.1016\/j.jneuroim.2013.08.011_bb0050","first-page":"S145","article-title":"No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to \u03b14\u03b27 integrin (Digestive Disease Week 2010 abstract 1008)","volume":"138","author":"Parikh","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrd3974","article-title":"Challenges and approaches for the development of safer immunomodulatory biologics","volume":"12","author":"Sathish","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0065","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0070","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2013.08.011_bb0085","series-title":"TYSABRI\u00ae (natalizumab) package insert","year":"2011"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572813002324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572813002324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:21:27Z","timestamp":1759047687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572813002324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":15,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0165572813002324"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.011","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}